Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MediciNova (MNOV; Osaka:4875) said it will discontinue development of MN-305 for insomnia after the
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury